The Centre for Immunology & Infection (C2i) uses novel technology platforms for biomarker discovery and the development of new vaccine and therapeutic strategies.
The C2i is the fruit of a long-standing partnership of more than 20 years between the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) and the Institut Pasteur, two major institutions combining their expertise to establish this centre of excellence.
This major initiative, funded by the Innovation and Technology Fund, adopts innovative strategies to identify and contain emerging infectious diseases and transform Hong Kong and the Greater Bay Area into a global hub of knowledge and research.
The C2i builds on the individual strengths of HKUMed and the Institut Pasteur. HKUMed’s School of Public Health has successful projects under the Area of Excellence programme and Theme-based Research Scheme, while Institut Pasteur is co-ordinator of the Milieu Interieur consortium that has drawn on rich genotype and phenotype datasets from 1,000 people of French descent to generate biomarkers for therapy and vaccine development.
The two institutions also count a strategic partnership that began in 2000 with HKU-Pasteur and has since advanced the understanding and treatment of infectious diseases.